AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

10 stories found

A wall of 1,357 medical-device approval tiles narrows to three illuminated patient-outcome records beside an empty hospital evidence chart.
Social good & healthUnited States · Global implications+3 clusters01

Only three of 1,357 FDA-authorized AI medical devices were evaluated on patient outcomes

A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.

5 min
Several luminous designed protein binders attach to a transparent molecular target above a physical laboratory assay tray.
Social good & healthGlobal+4 clusters02

Claude designs protein binders that survive wet-lab testing

Anthropic reports that Claude Opus 4.8 and Mythos Preview designed protein binders against 15 targets and succeeded against 14 after external laboratories produced and tested the designs. Reported hit rates ranged from 22.6 percent to 35.1 percent depending on the setup, above the 10 to 15 percent that Anthropic says is typical in current campaigns. The models orchestrated existing protein-design and folding tools with minimal human scientific guidance, producing 354 confirmed binders from 1,320 designs. This is a meaningful result because physical testing separates a scientific claim from a plausible-looking output. It is not a finished drug. Minibinders are an early design step, one target failed, additional characterization is planned, and the campaigns used substantial compute and specialist infrastructure. The same autonomy is dual-use, so Anthropic says its strongest biological capabilities remain restricted while it develops scientist access. The breakthrough and the control problem arrive together.

7 min
A strand of artificial intelligence code becomes a bacteriophage above a laboratory petri dish, marking the transition from digital design to living replication.
Social good & healthUnited States+4 clusters03

Scientists used AI to design viable viruses. The safety boundary just crossed into biology

Scientists used genome language models to design 16 viable bacteriophages that infected and killed the bacterium E coli in laboratory tests. The New York Times reports the peer-reviewed publication of work in which researchers generated thousands of candidate genomes, synthesized 285 designs, and identified 16 functional phages. These are viruses that target bacteria, not humans; Arc Institute says the models excluded eukaryotic viruses from training and the working phages showed restricted host range in testing. The result is both a therapeutic opportunity and a dual-use warning. AI-assisted phage design could help attack antibiotic-resistant bacteria, but it also proves that generative output can become a replicating biological system once synthesis and experimentation enter the chain.

5 min
A human speech bubble and an AI speech bubble converging around a heart-shaped support signal with an actionable-steps checklist.
Social good & healthUnited Kingdom+4 clusters04

AI chatbots matched human emotional support in everyday situations

Five studies involving 1,233 participants compared responses from ChatGPT 4o, Claude 3.5 Sonnet, Gemini 1.5 Pro, and human participants across everyday, non-clinical emotional situations. The AI responses were rated as more supportive for anger and fear, performed about as well as people for sadness, and still helped when recipients correctly suspected they came from a machine. The strongest factor was not generic validation but specific, actionable guidance.

3 min
A federal AI and supercomputing hub connecting health data, drug discovery, infrastructure materials, and scientific research.
Social good & healthUnited States+3 clusters05

A $5 billion federal push links AI to health, infrastructure and science

The U.S. government has committed more than $5 billion to expand the Genesis Mission, a multi-agency effort that combines federal datasets, Department of Energy supercomputers, research facilities, and AI tools. More than 15 agencies and 278 selected projects will target problems including chronic disease, pediatric cancer, drug discovery, resilient building materials, transportation maintenance, energy, manufacturing, agriculture, and national security.

3 min
A wearable bioelectronic patch linking biosensing, an AI decision node, human oversight, and controlled therapy in a closed loop.
Social good & healthGlobal+2 clusters06

Gao et al., “AI-powered closed-loop wearable bioelectronics for personalized and autonomous healthcare”

A Nature Sensors review argues that AI-powered closed-loop wearables could move healthcare devices beyond passive data collection by connecting continuous biosensing directly to AI-guided decisions and therapeutic intervention. The authors emphasize that clinical value depends on the coordinated system—sensing, control, treatment, and human oversight—not any component alone. Long-term interface stability, robust control, transparent safety mechanisms, and evidence of patient benefit remain prerequisites for scalable use.

3 min
A warped molecular structure resolving into a physically constrained chemical lattice.
Work & marketsGlobal+3 clusters07

Liu et al., “Integrating chemical priors and physical laws to mitigate hallucinations in structure-based drug design”

The NUS/Harbin-led team identifies a domain-specific form of generative-AI hallucination: molecular candidates can receive strong predicted binding scores while violating basic chemistry or producing physically impossible atomic arrangements. Its DrugRPG framework incorporates chemical-foundation-model priors and differentiable physical constraints during molecule generation, reducing severe steric clashes by 65.4% relative to the reported state-of-the-art baseline and increasing by 28.6% the share of generated candidates meeting combined potency, stability, and synthetic-feasibility criteria.

2 min
A clinical waveform and reinforcement-learning decision tree ending at an evidence gap.
Cognition & learningGlobal+2 clusters08

Tang et al., “Reinforcement learning for treatment decision-making in sepsis: a scoping review”

Reviewing 72 studies of reinforcement-learning systems for sepsis treatment, the authors found that every study was retrospective, 58 studies—80.6%—relied on the same MIMIC critical-care database, and only 10 used private datasets. Although many papers claimed that AI-derived treatment policies outperformed clinicians, variation in how patient states, treatment actions, rewards, and counterfactual outcomes were defined made those comparisons difficult to validate.

2 min
Cognition & learningGlobal+2 clusters09

Souei et al., “Artificial intelligence in deep brain stimulation for movement disorders: a systematic review and technology readiness assessment”

Researchers reviewed 239 peer-reviewed studies on AI-supported deep-brain stimulation and found a pronounced gap between reported algorithmic performance and clinical readiness. External validation remained rare, evaluations were predominantly retrospective and single-centre, and more than one-quarter of studies used small, high-dimensional datasets with elevated overfitting risk; most systems therefore remained at early-to-intermediate technology-readiness levels.

2 min
Technical failuresGlobal+2 clusters10

Shen et al., “Generalizable AI predicts immunotherapy outcomes across cancers and treatments”

A Harvard/Broad/MIT-linked team introduced COMPASS, a pan-cancer foundation model that predicts immune-checkpoint-inhibitor response from tumor transcriptomes and interpretable immune concepts. The model was trained on 10,184 tumors across 33 cancer types and reportedly outperformed 22 existing approaches across 16 clinical cohorts covering seven cancers and six immunotherapy agents, with predicted responders showing longer overall survival.

2 min